AIToday
Large Language ModelsRoboticsAI in HealthcareSiliconANGLE AIPublished: Sep 19, 2026, 06:00 JST

Anthropic opens AI-powered wet lab in San Francisco Bay Area

Anthropic opens AI-powered wet lab in San Francisco Bay Area

3 Key Points

  1. What happened

    Reuters reported that Anthropic PBC opened a wet lab in the San Francisco Bay Area, where robots powered by its Claude large language models will automate certain scientific tasks.

  2. Why it matters

    The facility suggests Anthropic is widening its life sciences push beyond drug discovery, since a spokesperson said the lab is "not for drug discovery specifically."

  3. What to watch

    A spokesperson said the Bay Area lab is "not for drug discovery specifically," so its value hinges on whether Claude-driven workflows prove useful across other biology subfields.

WHO IT HITSPharmaceutical and biotech R&D teams could gain an external partner for lab automation, and Anthropic may license discoveries to them rather than bringing drugs to market itself.

Not sure about something? Ask the AI

Summaries like this, in your inbox every morning.

Context & Analysis

Anthropic's new Bay Area wet lab arrives alongside a separate life sciences effort. In June, the company launched an effort to develop drugs for diseases the pharmaceutical sector isn't prioritizing — but the new facility is described by a spokesperson as "not for drug discovery specifically," which points to broader biology work.

The lab's use of Claude to control robots hints at the Model Hardware Standard, or MHS, a protocol that lets Claude control lab equipment and even spot and fix experiment errors. MHS was developed with HHMI, a Virginia-based medical research center, and in August Anthropic said the institute is among several organizations testing MHS-powered Claude workflows for lab equipment. That matters because mapping a new biological phenomenon usually requires several instruments to run in a specific order, with researchers manually writing scripts to coordinate them.

The stakes seem to hinge on how Anthropic positions itself relative to established drugmakers. The company told Reuters it is not "competing with pharma and biotech companies," and it plans to entrust some lab work to external partners. Since developing a new drug takes billions of dollars and more than a decade, offloading part of that work could simplify Anthropic's push — though whether that approach produces results outside drug discovery remains to be seen.

FAQ
Will Anthropic use the lab to discover drugs?
A spokesperson told Reuters the new Bay Area lab is "not for drug discovery specifically," suggesting it will also pursue other subfields of biology.
How well did Claude perform on protein design tests?
Anthropic evaluated Claude Mythos 5.1 ahead of its release earlier this month. The model generated 12 candidate molecules with a hit rate of 50%, compared with the 10% to 15% typical for protein design projects.
Is Anthropic competing with pharma companies?
Anthropic told Reuters it is not "competing with pharma and biotech companies," suggesting it may license Claude's discoveries instead of bringing them to market itself.
SiliconANGLE AIRead Original Article

Get the latest Large Language Models news every morning

For example, today's edition would include:

  • Goldman Sachs: consumer agents mark new AI growth phaseTop Companies AI · 1h ago
  • Mastercard rolls out AI-agent payments; only 7% would let a bot buyTop Companies AI · 1h ago
  • AWS's Matt Wood: AI is repeating the cloud playbookTop Companies AI · 1h ago

AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. Q&As are published on this page for other readers too.

Related Articles

Next articleMicron: memory caps AI performance, new supply not before 2028